Australia markets closed

Cambium Bio Limited (RGS.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.01200.0000 (0.00%)
At close: 03:59PM AEST

Cambium Bio Limited

16 Goodhope Street
Paddington, NSW 2021
61 1300 995 098

Full-time employees

Key executives

NameTitlePayExercisedYear born
Mr. Karolis RosickasChief Executive Officer250kN/AN/A
Prof. Graham Vesey Ph.D.Chief Scientific Officer & Executive Director39.28kN/A1965
Dr. Charlotte Morgan Ph.D.Head of Research & DevelopmentN/AN/AN/A
Ling Leung HangCompany SecretaryN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.


Regeneus Ltd, a clinical stage regenerative medicine company, develops cell-based therapies for the human health markets with a focus on osteoarthritis and other musculoskeletal disorders, neuropathic pain, and dermatology diseases in Australia. The company's platform technology includes Progenza, a multi-synergistic therapy, which has completed Phase I clinical trial for the treatment of osteoarthritis; and in pre-clinical stage to treat neuropathic pain. It also develops Sygenus that is in pre-clinical stage for the treatment of skin wound healing. The company was incorporated in 2007 and is headquartered in Paddington, Australia.

Corporate governance

Cambium Bio Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.